While Bharat Biotech vaccine Covaxin and Oxford-AstraZeneca vaccine Covishield continue to provide protection against the coronavirus; there are vaccines globally such as Johnson and Johnson and Sputnik V among others that have completed the third phase of clinical trials. Sputnik V has proved to be 91.6 per cent efficacious, with Sinopharm standing at 79.3 per cent, Johnson and Johnson at 85 per cent and Sinovac at 50.4 per cent
Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
News provided by
Share this article
TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/
Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy
Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status
Fourth cancer type where Libtayo has positive pivotal data; first-in-class survival results in cervical cancer follow first-in-class pivotal results in advanced BCC and advanced CSCC
Regulatory submissions planned in 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ:
Imugene Ltd secures BUY rating and target price of A$0 20 from Roth Capital Partners proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early .
SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy
Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status
Fourth cancer type where Libtayo has positive pivotal data; regulatory submission